Pharmaceutical company Hypera is registering a growth in demand for over-the-counter drugs since the end of last year, a trend that has been repeated in early 2022, company executives said on Friday (25).
“The big difference in the market is that people started to treat Covid-19 more and more like a flu, very different from what happened back then”, amidst the scenario of increased vaccination in the country, said the director of relations with Hypera investors, Adalmario Couto, in a conference with analysts.
“In addition to the additional demand due to the increase in cases of Covid and flu, it has acceleration in several categories, such as supplementation”, said the Executive. He referred to products like vitamin D, vitamin C, which Hypera joined last year.
The company announced the night before the high sell-out estimate, when the product is purchased by the consumer in a pharmacy, for example, in the first two months of 2022 of about 30% year on year, a level above the expectation of growth in the Marketplace. The company also announced a 24% growth projection in operating income measured by Ebitda (earnings before interest, taxes, depreciation and amortization) this year.
Asked about possible mergers and acquisitions, given the robustness of the result and the projections for this year, the President of Hypera, Breno de Oliveira, said that “certainly” the company will not make relevant moves this year.
“In the short term, the focus is organic investment and deleveraging and shareholder remuneration”, said the executive.
I have over 8 years of experience in the news industry. I have worked for various news websites and have also written for a few news agencies. I mostly cover healthcare news, but I am also interested in other topics such as politics, business, and entertainment. In my free time, I enjoy writing fiction and spending time with my family and friends.
